LEADER 04591nam 2200553 450 001 9910798274803321 005 20230808192337.0 010 $a1-68108-233-0 035 $a(CKB)3710000000627717 035 $a(EBL)4504170 035 $a(MiAaPQ)EBC4504170 035 $a(EXLCZ)993710000000627717 100 $a20160503h20162016 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $2rdacontent 182 $2rdamedia 183 $2rdacarrier 200 00$aAdvances in cancer drug targets$hVolume 3 /$fAtta-ur-Rahman, editor ; contributors Alain J. P. Alix [and thirty seven others] 210 1$aSharjah, United Arab Emirates :$cBentham Science Publishers,$d2016. 210 4$dİ2016 215 $a1 online resource (278 p.) 225 0 $aAdvances in Cancer Drug Targets,$x2213-9915 ;$vVolume 3 300 $aDescription based upon print version of record. 311 $a1-68108-234-9 320 $aIncludes bibliographical references at the end of each chapters and index. 327 $aCONTENTS; PREFACE ; List of Contributors ; Neutrophil Elastase as a Target in Lung Cancer: the State of the Art ; 1. INTRODUCTION: NEUTROPHIL ELASTASE/?-1ANTITRYPSIN IMBALANCE AS A LINK BETWEEN CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND LUNG CANCER; 2. MULTIFACETED FUNCTIONS OF NEUTROPHIL ELASTASE IN LUNG CANCER; 3. ENDEGNENOUS NEUTROPHIL ELASTASE INHIBITORS; 3.1. Proteinaceous Inhibitors; 3.2. Natural Compounds; 3.2.1. Glycosaminoglycans; 3.2.2. Phenolics; 3.2.3. Triterpenoids ; 3.2.4. Fatty Acids and Peptide Derivatives; 4. DESIGN OF DUAL NEUTROPHIL ELASTASE / MMP INHIBITORS 327 $aDESIGN OF DUAL HNE-MMP INHIBITORSCONCLUDING REMARKS; ADDITIONAL MATERIAL; 1. Molecular Modeling and Molecular Graphics; 2. Ligand and Receptor Preparation; 3. Docking Protocol; CONFLICT OF INTEREST; DISCLOSURE; ACKNOWLEDGEMENTS; ABBREVIATIONS; REFERENCES; Inhibition of Membrane Complement Inhibitor Expression (CD46, CD55, CD59) by siRNA Sensitizes Tumor Cells to Complement Attack ; INTRODUCTION; MATERIALS AND METHODS; Cell Culture; SiRNA Sequences; SiRNA Transfection; Flow Cytometry; Complement-mediated Cytotoxicity Assay (CDC); C3-binding Studies; Real-Time RT-PCR; Statistical Analysis 327 $aRESULTSDesign of siRNAs Specific for CD46, CD55 and CD59; SiRNA-mediated Downregulation of mCRP Expression; siRNA-mediated Augmentation of Tumor Cell Complement Lysis and Opsonization; Time-course of siRNA-induced mCRP Inhibition; Stable Downregulation of CD59 Using an Hairpin siRNA Expression Vector; DISCUSSION; CONFLICT OF INTEREST; DISCLOSURE; ACKNOWLEDGEMENT; ABBREVIATIONS; REFERENCES; Points of Therapeutic Intervention along the Wnt Signaling Pathway in Hepatocellular Carcinoma ; INTRODUCTION; THE WNT SIGNALING PATHWAY; Overview of the Wnt Signaling; The Wnt/?-catenin Pathway 327 $aAberrant Activation of the Wnt/?-catenin Pathway in HCCTARGETING THE WNT/?-CATENIN PATHWAY IN HCC; Targeting the Upstream Components; Endogenous Inhibitors of the Ligand/Receptor Complex; Targeting Wnt Ligands and FZD Receptors ; Targeting the Dishevelled Protein; Cellular Trafficking and Targets; Targeting the ?-catenin Destruction Complex; Targeting the ?-catenin/TCF Transcriptional Complex; Pitfalls in Targeting the Wnt/?-catenin Pathway; CONCLUSIONS AND PERSPECTIVES ; CONFLICT OF INTEREST; DISCLOSURE; ACKNOWLEDGMENT; ABBREVIATIONS; REFERENCES 327 $aCollaboration of Epithelial Mesenchymal Transition and Cancer Stem Cells: Sinister Routes for Chemoresistant Recurrent Ovarian Cancer INTRODUCTION; PATHOLOGY OF OVARIAN CANCER; TRANSITION FROM EPITHELIAL TO MESENCHYMAL PHENOTYPE AND THE PROGRESSION OF CANCER ; EVIDENCE OF EMT IN OVARIAN CANCER; STEM CELLS IN NORMAL OVARIES AND OVARIAN CANCER; SPHERE FORMATION AND THE CANCER STEM CELL PHENOTYPE OF THE OVARY; ASSOCIATION OF EMT AND CSCS: A MERGER FOR POTENTIAL CHEMORESISTANCE IN OVARIAN CANCER 327 $aCisplatin Induced EMT Generates Ovarian Cancer Stem-Like Cells: A Study on the OVCA 433 Cell Line as an Experimental Model 410 0$aAdvances in Cancer Drug Targets 606 $aCancer$xChemotherapy 606 $aDrug targeting 606 $aDrug delivery systems 615 0$aCancer$xChemotherapy. 615 0$aDrug targeting. 615 0$aDrug delivery systems. 676 $a616.994061 702 $aRahman$b Atta-ur- 702 $aAlix$b Alain J. P. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910798274803321 996 $aAdvances in cancer drug targets$93787519 997 $aUNINA LEADER 04154nam 2200685 450 001 9910784574803321 005 20230617001518.0 010 $a0-19-770555-3 010 $a0-19-539029-6 010 $a1-280-53445-1 010 $a0-19-974809-8 010 $a1-60256-847-2 035 $a(CKB)1000000000362974 035 $a(StDuBDS)AH24087711 035 $a(SSID)ssj0000101930 035 $a(PQKBManifestationID)11125242 035 $a(PQKBTitleCode)TC0000101930 035 $a(PQKBWorkID)10065326 035 $a(PQKB)11530293 035 $a(Au-PeEL)EBL3052082 035 $a(CaPaEBR)ebr10142428 035 $a(CaONFJC)MIL53445 035 $a(OCoLC)65199998 035 $a(Au-PeEL)EBL279587 035 $a(OCoLC)252605937 035 $a(MiAaPQ)EBC3052082 035 $a(EXLCZ)991000000000362974 100 $a20040308d2005 uy 0 101 0 $aeng 135 $auruz||||auuu| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aAmerican bioethics $ecrossing human rights and health law boundaries /$fGeorge J. Annas 210 1$aOxford ;$aNew York :$cOxford University Press,$d[2005] 215 $a1 online resource (xvi, 244 pages) 300 $aOriginally published: 2005. 311 $a1-4237-6340-8 311 $a0-19-516949-2 320 $aIncludes bibliographical references (pages 207-236) and index. 327 $aINTRODUCTION; I.BIOETHICS AND HUMAN RIGHTS; 1.BIOETHICS AND BIOTERRORISM; 2.HUMAN RIGHTS AND HEALTH; 3.THE MAN ON THE MOON; 4.THE ENDANGERED HUMAN; 5.THE RIGHT TO HEALTH; 6.CAPITAL PUNISHMENT; II.BIOETHICS AND HEALTH LAW; 7.CONJOINED TWINS; 8.PATIENT RIGHTS; 9.WHITE COAT POLICE; 10.PARTIAL BIRTH ABORTION; 11.THE SHADOWLANDS; 12.WASTE AND LONGING 330 $aBioethics was 'born in the USA' and the values American bioethics embrace are based on American law. This text crosses the borders between bioethics and law, but moves beyond the domestic law/bioethics struggles for dominance by exploring attempts to articulate universal principles on human rights. 330 $bBioethics was "born in the USA" and the values American bioethics embrace are based on American law, including liberty and justice. This book crosses the borders between bioethics and law, but moves beyond the domestic law/bioethics struggles for dominance by exploring attempts to articulate universal principles based on international human rights. The isolationism of bioethics in the US is not tenable in the wake of scientific triumphs like decoding the human genome, and civilizational tragedies like international terrorism. Annas argues that by crossing boundaries which have artificially separated bioethics and health law from the international human rights movement, American bioethics can be reborn as a global force for good, instead of serving mainly the purposes of U.S. academics. This thesis is explored in a variety of international contexts such as terrorism and genetic engineering, and in U.S. domestic disputes such as patient rights and market medicine. The citizens of the world have created two universal codes: science has sequenced the human genome and the United Nations has produced the Universal Declaration of Human Rights. The challenge for American bioethics is to combine these two great codes in imaginative and constructive ways to make the world a better, and healthier, place to live. 606 $aHuman rights$xMoral and ethical aspects 606 $aMedical laws and legislation$xMoral and ethical aspects 606 $aMedical laws and legislation$xMoral and ethical aspects$zUnited States 606 $aBioethics$zUnited States 615 0$aHuman rights$xMoral and ethical aspects. 615 0$aMedical laws and legislation$xMoral and ethical aspects. 615 0$aMedical laws and legislation$xMoral and ethical aspects 615 0$aBioethics 676 $a174/.957/0973 700 $aAnnas$b George J.$0922498 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910784574803321 996 $aAmerican bioethics$93867966 997 $aUNINA